课题基金 / 基金详情

PHASE I STUDY OF SEQUENTIAL CPT 11 & MITOMYCIN C

PHASE I STUDY OF SEQUENTIAL CPT 11 & MITOMYCIN C
序贯 CPT 11 的第一阶段研究
批准号：
6450071
负责人：
MIGUEL A VILLALONA-CALERO
金额：
$23.48万
依托单位：
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
依托单位国家：
美国
项目类别：
财政年份：
2000
资助国家：
美国
项目状态：
已结题
起止时间：
2000-12-01 至 2001-11-30
来源：
https://reporter.nih.gov/project-details/6450071
关键词：
antineoplastic antibiotics child (0-11) clinical research clinical trial phase I combination cancer therapy combination chemotherapy dihydrolipoamide dehydrogenase dosage drug interactions drug screening /evaluation enzyme activity human subject human therapy evaluation mitomycin C pharmacokinetics

项目摘要

项目成果

MIGUEL A VILLALONA-CALERO的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The objectives of this protocol are to determine the maximum tolerated dose of Mitomycin C (MMC) when given in combination with CPT-11, to determine if the pharmacokinetic behavior of CPT-11 is altered prior to administration of MMC, to determine the effect of CPT-11 and MMC on the expression of DT-Diaphorase and the Topo I gene, and to evaluate the antitumor activity of the combination.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors
Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors
Targeting Somatic Homologous Recombination in Solid Tumors
  • 批准号：
    8101174
  • 项目类别：
  • 资助金额：
    $52.22万
  • 财政年份：
    2010
  • 负责人：
    MIGUEL A VILLALONA-CALERO
  • 依托单位：
    OHIO STATE UNIVERSITY
Targeting Somatic Homologous Recombination in Solid Tumors
  • 批准号：
    8204586
  • 项目类别：
  • 资助金额：
    $51.66万
  • 财政年份：
    2010
  • 负责人：
    MIGUEL A VILLALONA-CALERO
  • 依托单位：
    OHIO STATE UNIVERSITY